We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Sites Stop Manufacturing Nuclear Medicines Over Quality Problems
Novartis Sites Stop Manufacturing Nuclear Medicines Over Quality Problems
Novartis has paused production of two radioligand cancer therapies manufactured at its Ivrea, Italy, and Millburn, N.J., plants after potential quality issues surfaced.